{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-24-000002","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.288297+00:00","generated_at":"2026-06-06T03:48:50.665659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"QuidelOrtho Q4 revenue $743M (-14% YoY); GAAP EPS $0.10, adj. EPS $1.17; FY24 guidance issued","bullets":["Q4 revenue $743M vs $867M YoY; non-respiratory +9%, respiratory -49%.","GAAP diluted EPS $0.10 (prior $0.45); adjusted diluted EPS $1.17 (prior $1.76).","Full-year 2023 revenue $3.0B; GAAP diluted loss $0.15; adjusted EBITDA $723M (24% margin).","FY24 guidance: revenue $2.76-3.07B; adj. EBITDA $565-720M; adj. EPS $2.40-3.07.","Received 510(k) for Savanna multiplex platform and CLIA waiver for Sofia 2 SARS Antigen+ FIA."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-24-000002","json":"https://secwatch.observer/filing/0001906324-24-000002.json","markdown":"https://secwatch.observer/filing/0001906324-24-000002.md","text":"https://secwatch.observer/filing/0001906324-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000002/0001906324-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000002/qdel-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:48:50.665659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88fab1c08e2aa3e3251903f139bc20ff5d363566","claim":"QuidelOrtho Corp updated its fourth quarter and full-year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"On February 13, 2024, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its fourth quarter and full year ended December 31, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on February 13, 2024 to discuss such results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000002/0001906324-24-000002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full-year ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}